Trial Profile
Phase IIb Open-label Trial of SUBA-Itraconazole in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Dec 2023
Price :
$35
*
At a glance
- Drugs Itraconazole (Primary)
- Indications Basal cell cancer; Carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms SCORING
- Sponsors INHIBITOR Therapeutics
- 19 Dec 2023 According to the Inhibitor Therapeutics media release, Scientific Advisory Board tasked with critical review of Phase 2b trial results to assess clinical usefulness prior to submission of New Drug Application to FDA
- 13 Dec 2023 Results presented in the Inhibitor Therapeutics Media Release
- 03 Aug 2020 Status changed from active, no longer recruiting to completed.